APM looks to have a small bounce backAPM seems to gain some reversal volume as all the support levels are smashed and the stock is making a bounce back.
APM trade ideas
$APM Target PTs 7-14 Long term PT 30 and higherAptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer
The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM) SACT-1, a repurposed small molecule compound for Neuroblastoma.
Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a Phase 1b/2a trial for SACT-1 in 2022.
Neuroblastoma is one of the most prevailing solid tumor cancers in children, representing 8% - 10% of all childhood tumors, accounting for around 15% of all cancer-related deaths in the pediatric population.
Aptorum received its first US patent regarding SACT-1 repurposed drug for various cancers earlier this week.
The SACT-1 invention provides a composition and method for treating or preventing the growth of cancerous tumors and/or delaying the onset of cancer from tumor-initiating cells.
Price Action: APM shares are up 30.3% at $1.59 during the premarket session on the last check Thursday.
See more from Benzinga
FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors
EXCLUSIVE: Alfi Inks AI Tech Deal For Improved Passenger Experience At BWI Thurgood Marshall Airport
APM 1Dtest
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. Its lead projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
APM: Descending triangle, confirmedDescending triangle, Confirmed
Pros
Descending volume
Volume spike on break out
PPS under 50MA
No data on 200MA
No data on 250MA
RS below 0 and descending
Overall bearish
No support under 1,37$
Price Target
PT1 = 2,11 (filled)
PT2 = 1,37
Could see lower
touch the resistance and have the potential to rise.touch the resistance and have the potential to rise.
APM Expanded FlatHello,
Be sure to comment, follow, like, and check out my profile for more trade ideas!
About Aptorum Group
Aptorum Group Limited (Nasdaq:APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group’s current drug pipeline includes indications in orphan diseases, infectious diseases and metabolic diseases, a number of which are targeted to enter clinical trial phases in H2 2020. Aptorum Group is also launching a women’s health supplement, Dioscorea Opposita Bioactive Nutraceutical Tablets, which will be commercialized soon.
Exclusive Interview with President of Aptorum Group
Good Luck
Cheers!
